from Reuters: Business News https://ift.tt/2CDx2m3
Sunday, September 9, 2018
Home »
business news
,
latest business news
» Roche faces UK pricing row over multiple sclerosis drug Ocrevus
Roche faces UK pricing row over multiple sclerosis drug Ocrevus
Roche faces a fresh row over drug pricing in Britain, following a decision by the body responsible for medicine use within the state health service not to approve its drug Ocrevus for treating a highly disabling form of multiple sclerosis (MS).

from Reuters: Business News https://ift.tt/2CDx2m3
from Reuters: Business News https://ift.tt/2CDx2m3
Related Posts:
Loan charge - retrospective tax bills for freelancersIT contractors, oil and gas workers, locum doctors, social workers and nurses who took advice from accountants, recruitment firms and tax advisers face unexpected tax demands. from BBC News - Business https://bbc.in/2HinywS … Read More
Richer Sounds boss wants 'to do the right thing'Julian Richer's decision to hand ownership of his company to staff confirms his unorthodox approach. from BBC News - Business https://bbc.in/2WLPgaH … Read More
Pilots 'raised Boeing safety fears' months before Ethiopia crashAmerican Airlines pilots reportedly raised concerns months before the second deadly 737 Max crash. from BBC News - Business https://bbc.in/2Hk5anj … Read More
Fears of flying Boeing’s 737 MAX won’t get in way of price conscious ticket shoppers: Reuters/IPSOS pollU.S. fliers still consider ticket prices the most important factor when choosing a flight, according to a Reuters/Ipsos poll, suggesting two fatal crashes of Boeing Co 737 MAX jets have had little impact on consumer sentiment… Read More
What's the secret of life satisfaction?It's not what you earn, it's the way that you spend it, say statisticians, but health's what gets results. from BBC News - Business https://bbc.in/2W7vwRN … Read More
'I feel sick at the prospect of welfare cuts'
People on long-term sickness and disability benefits have told the BBC they fear how cuts will affect them. from BBC News https://ift.tt/2...
0 comments:
Post a Comment